ARWR R&D to Revenue
Arrowhead Pharmaceuticals Inc · R&D to Revenue
ARWR R&D to Revenue
Latest reported263.41%period ending
ARWR Quarterly R&D/Revenue (0.00% → 263.41%)
Latest values, visible window
High-resolution chart · PNG
ARWR r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 263.4088% | |
| 234.9607% | |
| 67.114% | |
| 68.1115% | |
| 584.7517% | |
| 24.5255% | |
| 5,480.08% | |
| 0% | |
| 0% | |
| 0% | |
| 3,172.0642% | |
| 598.8756% | |
| 580.6382% | |
| 49.6462% | |
| 130.1586% | |
| 256.9153% | |
| 215.9077% | |
| 48.6176% | |
| 231.7687% | |
| 171.789% | |
| 129.2737% | |
| 136.2257% | |
| 171.5955% | |
| 548.4907% | |
| 113.9346% | |
| 119.9573% | |
| 75.5822% | |
| 51.5258% | |
| 42.8447% | |
| 40.7671% | |
| 47.3188% | |
| 131.2349% | |
| 1,496.1213% | |
| 1,670.041% | |
| 240.2374% | |
| 95.0265% | |
| 73.9204% | |
| 77.6417% | |
| 218.2352% | |
| 37,349.1136% | |
| 23,806.1668% | |
| 22,904.7451% | |
| 23,631.6183% | |
| 23,747.2823% | |
| 6,052.8485% | |
| 49,791.04% | |
| 10,391.9836% | |
| 19,241.8537% | |
| 14,610.7429% | |
| 11,923.3051% | |
| 7,161.1749% | |
| 7,422.6629% | |
| 4,014.9189% | |
| 4,857.1863% | |
| 991.5141% | |
| 4,673.0537% | |
| 2,544.4748% | |
| 4,347.8112% | |
| 3,210.0927% | |
| 0% | |
| 0% | |
| 0% | |
| 763.7815% | |
| 141.0312% | |
| 0% | |
| 5.6221% | |
| 187.6084% | |
| 501.8871% | |
| 95.3093% | |
| 639.3159% | |
| 554.1081% | |
| -9,414.4169% | |
| 1,423.0338% | |
| 231.5862% | |
| 413.2167% | |
| 1,109.6238% | |
| 1,375.428% | |
| 0% | |
| 13,412.6758% | |
| 11,833.3707% | |
| 430.8558% | |
| 5,422.0226% | |
| 1,046.8432% | |
| 598.6651% | |
| 775.9665% | |
| 565.6686% | |
| 500.3522% | |
| 225.4528% | |
| 624.2876% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |